Inibição e reversão da agregação plaquetária de eqüinos in vitro com o uso de ketoprofeno, fenilbutazona e flunixim meglumine
Several diseases may lead to platelet pre-activation and hypercoagulability states in horses. The activity of many drugs against platelet aggregation may, not only contribute to the evaluation of a disease but also its response to the therapy. With the aim to study in vitro prevention and reversion...
| Autor principal: | LEME, Fabiola de Oliveira Paes |
|---|---|
| Outros Autores: | WURZINGER, Laurenz, ALVES, Geraldo Eleno Silveira, BICALHO, Adriane Pimenta da Costa-Val, BARBOSA, Marcos Pinott, PAES, Paulo Ricardo de Oliveira, OLIVEIRA, Marcos Enê Chaves |
| Grau: | Artigo |
| Idioma: | por |
| Publicado em: |
2016
|
| Assuntos: | |
| Acesso em linha: |
http://repositorio.ufpa.br/jspui/handle/2011/7056 |
| Resumo: |
|---|
|
Several diseases may lead to platelet pre-activation and hypercoagulability states in horses. The activity of many drugs against platelet aggregation may, not only contribute to the evaluation of a disease but also its response to the therapy. With the aim to study in vitro prevention and reversion of platelet aggregation, the non steroidal anti-inflammatory drug (NSAID): ketoprophen, phenylbutazone and flunixin-meglumin were evaluated. The comparison demonstrated that phenylbutazone and ketoprophen prevented platelet aggregation induced by ADP better than flunixin-meglumin, in a superior manner to the monoclonal antibody Reopro, and in a better way than the membrane receptor blockers Ro-438857 and RGDS. The reversion of platelet aggregation demonstrated that even phenylbutazone or ketoprophen have a dose-dependent effect. |